With two forms of influenza vaccine, BioCryst Pharma has the potential to emerge as one of the world’s top biotech companies in the fight against the swine flu. BioCryst stock has increase 450% since April 2009 reaching the best swine flu stock performed: Novavax NVAX with a 500% plus during the same period.

Since the first swine flu symptoms invaded the media, Antigenics share price has increased 300%, not because of their relationship to the swine flu virus but because of the expectation of Oncophage Antigenics, the cancer vaccine. The first flu vaccine containing their patented QS21 adjuvant could reach the market and provide revenues to Antigenic by 2012.

With their innovative and top selling product, the PFL N95 mask, currently meets both WHO and CDC protection levels in order to project individuals from the spreads of the influenza virus from individuals suffering the swine flu symptoms. Alpha Pro Tech share price has increased 250% since April 2009. More to come?

Although not currently linked with research and development for products directly related to the H1N1 virus, Advanced Life Sciences has a promising pipeline of clinical and preclinical products related to respiratory infections which is the most common complication of the swine flu virus.

With their best seller Quidel Influenza Test, Quidel Corp. share price has increased over 80% since April 2009. Recognized as one of the best distributors of the top pharmaceutical companies, Quidel Corp. is looking to emerge as a leading player in the early detection of one of the fastest growing epidemics, the swine flu.

Sinovac Biotech is one of the top pharmaceutical companies that has a swine flu vaccine being tested with possible production starting in September. Since the first swine flu symptoms were reported in Mexico in April 2009, Sinovac Biotech stock has jumped over 200% exceeding analyst expectations. How much higher can Sinovac Biotech share price go?

Roche share price hasn’t exceeded the 20% return since the first swine flu symptoms were reported in Mexico in April 2009, a clear indication that Tamiflu is not the solution to the swine flu pandemic. Relenza, produced by GlaxoSmithKline, is also reporting the same ineffective results primarily over children under 12.

The 500% plus increase of Novavax share price since the swine flu symptoms invaded the media, puts this company at the peak of the high-yielding list of stocks to watch, but also, at the highest risk. For how much longer will Novavax Pharmaceuticals be able to sustain the share price?

With advanced orders from the UK government for over 60 million doses of its swine flu vaccine, GlaxoSmithKline UK is preparing to sell £3bn worth of swine flu drugs this year. Glaxo is Britain’s biggest pharmaceutical supplier and has deals with world governments for its antiviral treatment Relenza, which can relieve swine flu symptoms. Is that good enough to consider this company as an investment option?

CSL was one of the first to produce a flu vaccine and with potential contracts with the Australian government to supply 90% of its vaccine orders as well as orders form the US government totalling $180 million (US dollars); it makes CSL a very attractive investment choice. Howeve, CSL management has struggled to convert their achievements into profit, so CSL share price has remained stagnant for over 18 months.